Olema Pharmaceuticals, Inc. announced a new clinical trial collaboration and supply agreement with Pfizer Inc.
The collaboration aims to evaluate the combination of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer.
The study will involve approximately 35 patients with initiation anticipated in H2 2025.
Study Collaboration
Phase 1b/2 study to assess safety and combinability of palazestrant and atirmociclib in ER+/HER2- metastatic breast cancer.
Potential Novel Combination
Results to inform a potential pivotal Phase 3 trial of the novel combination in the frontline metastatic breast cancer setting.
Olema's Focus
Continued focus on transforming the treatment paradigm of metastatic breast cancer with ongoing pivotal studies and combination trials.
- The collaboration with Pfizer represents a significant step in Olema's commitment to advancing therapies for breast cancer.
- Exploring the combination of palazestrant and atirmociclib could lead to improved treatment options for patients with ER+/HER2- metastatic breast cancer.
With this new clinical trial collaboration, Olema Pharmaceuticals aims to expand treatment options for metastatic breast cancer patients and potentially pave the way for a pivotal Phase 3 trial.